Citations

Clear

4 citation(s) found for "Anthony, Daniel".

Permissive central tolerance plus defective peripheral checkpoints license pathogenic memory B cells in CASPR2-antibody encephalitis
Sun, Bo , Fernandes, Dominique , Soltys, John , Paneva, Sofija , Harrison, Ruby , Harrison, Anna, Makuch, Mateusz , Fichtner, Miriam L. , Donat, Robert F. , Akdeniz, Deniz, Bayuangga, Halwan Fuad , Im, Min Gyu , Williams, Robyn , VASCONCELOS, ANA RAQUEL GOUVEIA , Thomsen, Selina, Fower, Andrew , Sun, Ruyue, Fox, Hannah , Mgbachi, Victor , Davies, Alexander J. , Tseng, Mandy , Handel, Adam E. , Kelly, Mark , Zhao, Meng , Bancroft, James , Bashford-Rogers, Rachael , Pluvinage, John V. , Dandekar, Ravi , Alvarenga, Bonny D. , Dustin, Lynn B. , Rinaldi, Simon , Owens, Raymond J. , Anthony, Daniel C. , Bennett, David , Davis, Simon J. , Wilson, Michael R. , O’Connor, Kevin C. , Carvalho, Ana Luı́sa , Irani, Sarosh R. , Kienzler, Anne-Kathrin , Paneva, Sofija , Harrison, Ruby , Harrison, Anna L , Fichtner, Miriam L , Bayuangga, Halwan , Im, Min Gyu , Vasconcelos, Ana , Fower, Andrew , Fox, Hannah , Davies, Alexander , Tseng, Mandy , Handel, Adam , Kelly, Mark , Zhao, Meng , Bancroft, James , Pluvinage, John V , Dandekar, Ravi , Alvarenga, Bonny D , Dustin, Lynn B , Rinaldi, Simon , Owens, Ray , Anthony, Daniel , Bennett, David L , Davis, Simon J , Wilson, Michael R , O'Connor, Kevin C , Carvalho, Ana Luisa , Irani, Sarosh R , Sun, Bo , Williams, Robyn L , Ramanathan, Sudarshini , Sun, Ruyue, Waters, Patrick

Mayo Clinic

Science Advances | April 16, 2025 | Volume: 11 | Issue: 16 | Pages: No page available

10.1126/sciadv.adr9986 | PMID 40238887 Get It

Autoantibody-mediated diseases targeting one autoantigen provide a unique opportunity to comprehensively understand the development of disease-causing B cells and autoantibodies. Convention suggests that such autoreactivities are generated during germinal center reactions. Here, we explore earlier immune checkpoints, focusing on patients with contactin-associated protein-like 2 (CASPR2)–autoantibody encephalitis. In both disease and health, high (~0.5%) frequencies of unmutated CASPR2-reactive naïve B cells were identified. By contrast, CASPR2-reactive memory B cells were exclusive to patients, and their B cell receptors demonstrated affinity-enhancing somatic mutations with pathogenic effects in neuronal cultures and mice. The unmutated, precursor memory B cell receptors showed a distinctive balance between strong CASPR2 reactivity and very limited binding across the remaining human proteome. Our results identify permissive central tolerance, defective peripheral tolerance, and autoantigen-specific tolerance thresholds in humans as sequential steps that license CASPR2-directed pathology. By leveraging the basic immunobiology, we rationally direct tolerance-restoring approaches, with an experimental paradigm applicable across autoimmunity.
Permissive central tolerance plus defective peripheral checkpoints licence pathogenic memory B cells in CASPR2-antibody encephalitis
Fernandes, Dominique , Paneva, Sofija , Harrison, Ruby , Harrison, Anna, Makuch, Mateusz , Donat, Robert F. , Akdeniz, Deniz, Williams, Robyn , Thomsen, Selina, Fower, Andrew , Sun, Ruyue, Fox, Hannah , Mgbachi, Victor , Tseng, Mandy , Kelly, Mark , Bashford-Rogers, Rachael , Pluvinage, John V. , Dandekar, Ravi , Alvarenga, Bonny D. , Rinaldi, Simon , Anthony, Daniel C. , Wilson, Michael R. , Soltys, John , Irani, Sarosh R. , Harrison, Anna L, Irani, Sarosh R , Wilson, Michael R , Paneva, Sofija , Fox, Hannah , Kelly, Mark , Rinaldi, Simon , Anthony, Daniel , Sun, Bo , Kienzler, Anne-Kathrin , Ramanathan, Sudarshini , Fichtner, Miriam L. , Bayuangga, Halwan Fuad , Im, Min Gyu, Vasconcelos, Ana Tereza Ribeiro de , Sun, Ruyue, Davies, Alexander J. , Handel, Adam E. , Zhao, Meng , Bancroft, James , Dustin, Lynn B. , Owens, Raymond J. , Bennett, David , Waters, Patrick , Davis, Simon J. , O’Connor, Kevin C. , Carvalho, Ana Luı́sa

Mayo Clinic

No container title available | January 14, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1101/2025.01.14.631703 | PMID 39868113 Get It

Abstract Autoimmunity affects 10% of the population. Within this umbrella, autoantibody-mediated diseases targeting one autoantigen provide a unique opportunity to comprehensively understand the developmental pathway of disease-causing B cells and autoantibodies. While such autoreactivities are believed to be generated during germinal centre reactions, the roles of earlier immune checkpoints in autoantigen-specific B cell tolerance are poorly understood. We address this concept in patients with CASPR2-autoantibody encephalitis and healthy controls. In both groups, comparable and high (∼0.5%) frequencies of unmutated CASPR2-reactive naïve B cells were identified. By contrast, CASPR2-reactive memory B cells were exclusive to patients, and their B cell receptors demonstrated affinity-enhancing somatic mutations with heterogenous binding kinetics. These effector molecules possessed epitope-dependent pathogenic effects in vitro neuronal cultures and in vivo. The unmutated common ancestors of these memory B cells showed a distinctive balance between strong CASPR2 reactivity and very limited binding across the remaining human proteome. Our results are the first to propose mechanisms underlying autoantigen-specific tolerance in humans. We identify permissive central tolerance, defective peripheral tolerance and heterogenous autoantibody binding properties as sequential pathogenic steps which licence CASPR2-directed pathology. By leveraging the basic immunobiology, we rationally direct tolerance-restoring approaches in CASPR2-antibody diseases. This paradigm is applicable across autoimmune conditions.
Distinct plasma metabolomic signatures differentiate autoimmune encephalitis from drug‐resistant epilepsy
Xiong, Wenzheng , May, Jeanne Tan May, Demmers, Tor, Ceronie, Bryan , Ramesh, Archana , McGinty, Ronan N. , Michael, Sophia , Torzillo, Emma, Anthony, Daniel C. , Irani, Sarosh R. , Irani, Sarosh R , Anthony, Daniel , Yeo, Tianrong , Sen, Arjune , Probert, Fay

Mayo Clinic

Annals of Clinical and Translational Neurology | June 22, 2024 | Volume: 11 | Issue: 7 | Pages: 1897-1908

10.1002/acn3.52112 | PMID 39012808 Get It

Abstract Objective Differentiating forms of autoimmune encephalitis (AE) from other causes of seizures helps expedite immunotherapies in AE patients and informs studies regarding their contrasting pathophysiology. We aimed to investigate whether and how Nuclear Magnetic Resonance (NMR)‐based metabolomics could differentiate AE from drug‐resistant epilepsy (DRE), and stratify AE subtypes. Methods This study recruited 238 patients: 162 with DRE and 76 AE, including 27 with contactin‐associated protein‐like 2 (CASPR2), 29 with leucine‐rich glioma inactivated 1 (LGI1) and 20 with N‐methyl‐ d ‐aspartate receptor (NMDAR) antibodies. Plasma samples across the groups were analyzed using NMR spectroscopy and compared with multivariate statistical techniques, such as orthogonal partial least squares discriminant analysis (OPLS‐DA). Results The OPLS‐DA model successfully distinguished AE from DRE patients with a high predictive accuracy of 87.0 ± 3.1% (87.9 ± 3.4% sensitivity and 86.3 ± 3.6% specificity). Further, pairwise OPLS‐DA models were able to stratify the three AE subtypes. Plasma metabolomic signatures of AE included decreased high‐density lipoprotein (HDL, −(C H 2 ) n −, –C H 3 ), phosphatidylcholine and albumin (lysyl moiety). AE subtype‐specific metabolomic signatures were also observed, with increased lactate in CASPR2, increased lactate, glucose, and decreased unsaturated fatty acids (UFA, –C H 2 CH=) in LGI1, and increased glycoprotein A (GlycA) in NMDAR‐antibody patients. Interpretation This study presents the first non‐antibody‐based biomarker for differentiating DRE, AE and AE subtypes. These metabolomics signatures underscore the potential relevance of lipid metabolism and glucose regulation in these neurological disorders, offering a promising adjunct to facilitate the diagnosis and therapeutics.
Trajectory of Improvement in Myelopathic Symptoms From 3 to 12 Months Following Surgery for Degenerative Cervical Myelopathy
Khan, Inamullah , Archer, Kristin R. , Wanner, John Paul , Bydon, Mohamad , Pennings, Jacquelyn S. , Sivaganesan, Ahilan, Knightly, John J. , Foley, Kevin T. , Bisson, Erica F. , Shaffrey, Christopher I. , McGirt, Matthew J., Asher, Anthony L. , Devin, Clinton J. , MD, QOD Vanguard Sites Asher Anthony L MD McGirt Matthew J MD Devin Clinton J MD Foley Kevin T MD Sorenson Jeffrey M MD Briggs Thomas B MD Kremer Adam MD Griffitt Wesley E MD Bisson Erica F MD Shaffrey Mark E Shaffrey Christopher MD Fassett Daniel MD Oetting Gregory MD Elowitz Eric H MD Rumana Christopher, Sorenson, Jeffrey, Briggs, Thomas B., Kremer, Adam, Griffitt, Wesley E., Shaffrey, Mark E., Fassett, Daniel R. , Oetting, Gregory, Elowitz, Eric , Rumana, Christopher S., MD, QOD Vanguard Sites Asher Anthony L MD McGirt Matthew J MD Devin Clinton J MD Foley Kevin T MD Sorenson Jeffrey M MD Briggs Thomas B MD Kremer Adam MD Griffitt Wesley E MD Bisson Erica F MD Shaffrey Mark E Shaffrey Christopher MD Fassett Daniel MD Oetting Gregory MD Elowitz Eric H MD Rumana Christopher

Mayo Clinic

Neurosurgery | July 31, 2019 | Volume: 86 | Issue: 6 | Pages: 763-768

10.1093/neuros/nyz325 | PMID 31435676 Get It

Abstract BACKGROUND Degenerative cervical myelopathy (DCM) is a progressive disease resulting from cervical cord compression. The modified Japanese Orthopaedic Association (mJOA) is commonly used to grade myelopathic symptoms, but its persistent postoperative improvement has not been previously explored. OBJECTIVE To utilize the Quality Outcomes Database (QOD) to evaluate the trajectory of outcomes in those operatively treated for DCM. METHODS This study is a retrospective analysis of prospectively collected data. The QOD was queried for patients undergoing elective surgery for DCM. Patients were divided into mild (≥14), moderate (9-13), or severe (<9) categories for their baseline severity of myelopathic symptoms (mJOA scores). A parsimonious multivariable logistic regression model was fitted with 2 points improvement on mJOA from 3- to 12-mo follow-up as the outcome of interest. RESULTS A total of 2156 patients who underwent elective surgery for DCM and had complete 3- and 12-mo follow-up were included in our analysis. Patients improved significantly from baseline to 3-mo on their mJOA scores, regardless of their baseline mJOA severity. After adjusting for the relevant preoperative characteristics, the baseline mJOA categories had significant impact on outcome of whether a patient keeps improving in mJOA score from 3 to 12 mo postsurgery. Patient with severe mJOA score at baseline had a higher likelihood of improvement in their myelopathic symptoms, compared to patients with mild mJOA score in. CONCLUSION Most patients achieve improvement on a shorter follow-up; however, patients with severe symptoms keep on improving until after a longer follow-up. Preoperative identification of such patients helps the clinician settling realistic expectations for each follow-up timepoint.